Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.68), $0.44 worse than the analyst estimate of ($2.24). Revenue for the quarter came in at $36.5 million versus the consensus estimate of $36.85 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.